» Articles » PMID: 35072851

Current Challenges in Metastasis Research and Future Innovation for Clinical Translation

Overview
Specialty Oncology
Date 2022 Jan 24
PMID 35072851
Authors
Affiliations
Soon will be listed here.
Abstract

While immense strides have been made in understanding tumor biology and in developing effective treatments that have substantially improved the prognosis of cancer patients, metastasis remains the major cause of cancer-related death. Improvements in the detection and treatment of primary tumors are contributing to a growing, detailed understanding of the dynamics of metastatic progression. Yet challenges remain in detecting metastatic dissemination prior to the establishment of overt metastases and in predicting which patients are at the highest risk of developing metastatic disease. Further improvements in understanding the mechanisms governing metastasis have great potential to inform the adaptation of existing therapies and the development of novel approaches to more effectively control metastatic disease. This article presents a forward-looking perspective on the challenges that remain in the treatment of metastasis, and the exciting emerging approaches that promise to transform the treatment of metastasis in cancer patients.

Citing Articles

A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8 T cell fitness in solid tumours.

Pretto S, Yu Q, Bourdely P, Trusso Cafarello S, Van Acker H, Verelst J Nat Metab. 2025; .

PMID: 40065102 DOI: 10.1038/s42255-025-01233-w.


Innovative laboratory techniques shaping cancer diagnosis and treatment in developing countries.

Lawal A, Ogunniyi T, Oludele O, Olorunfemi O, Okesanya O, Ogaya J Discov Oncol. 2025; 16(1):137.

PMID: 39921787 PMC: 11807038. DOI: 10.1007/s12672-025-01877-w.


Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.

Skalickova M, Hadrava Vanova K, Uher O, Leischner Fialova J, Petrlakova K, Masarik M Front Immunol. 2025; 15:1479483.

PMID: 39850897 PMC: 11754201. DOI: 10.3389/fimmu.2024.1479483.


Pan-cancer drivers of metastasis.

Lusby R, Demirdizen E, Inayatullah M, Kundu P, Maiques O, Zhang Z Mol Cancer. 2025; 24(1):2.

PMID: 39748426 PMC: 11697158. DOI: 10.1186/s12943-024-02182-w.


ANGPTL3 overcomes sorafenib resistance via suppression of SNAI1 and CPT1A in liver cancer.

Lin Y, Chen C, Chi H, Wu M, Lai M, Yeh C Transl Oncol. 2024; 52():102250.

PMID: 39708716 PMC: 11732165. DOI: 10.1016/j.tranon.2024.102250.


References
1.
Albrengues J, Shields M, Ng D, Park C, Ambrico A, Poindexter M . Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018; 361(6409). PMC: 6777850. DOI: 10.1126/science.aao4227. View

2.
Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G . Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18(6):883-91. PMC: 3645291. DOI: 10.1038/nm.2753. View

3.
Montagner M, Bhome R, Hooper S, Chakravarty P, Qin X, Sufi J . Crosstalk with lung epithelial cells regulates Sfrp2-mediated latency in breast cancer dissemination. Nat Cell Biol. 2020; 22(3):289-296. PMC: 7610690. DOI: 10.1038/s41556-020-0474-3. View

4.
Poruk K, Gay D, Brown K, Mulvihill J, Boucher K, Scaife C . The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013; 13(3):340-51. PMC: 4419808. DOI: 10.2174/1566524011313030003. View

5.
Wang J, Li S, Liu Y, Zhang C, Li H, Lai B . Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med. 2019; 9(1):361-373. PMC: 6943094. DOI: 10.1002/cam4.2673. View